 Ann Kulungowski
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 8 | 2022 | 47 | 3.490 |
Why?
| | Lymphatic Abnormalities | 3 | 2020 | 18 | 1.840 |
Why?
| | Sclerotherapy | 2 | 2018 | 20 | 1.240 |
Why?
| | Secondary Prevention | 2 | 2018 | 227 | 1.100 |
Why?
| | Wounds, Penetrating | 2 | 2023 | 77 | 0.980 |
Why?
| | Hemangioma | 5 | 2016 | 41 | 0.910 |
Why?
| | Surgical Wound | 1 | 2023 | 19 | 0.900 |
Why?
| | Chylous Ascites | 1 | 2022 | 6 | 0.880 |
Why?
| | Chylothorax | 1 | 2022 | 12 | 0.870 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2022 | 20 | 0.870 |
Why?
| | Neutropenia | 1 | 2023 | 133 | 0.870 |
Why?
| | Respiration Disorders | 1 | 2022 | 66 | 0.830 |
Why?
| | Wounds, Nonpenetrating | 3 | 2019 | 285 | 0.790 |
Why?
| | Intestines | 2 | 2022 | 332 | 0.720 |
Why?
| | Surgery Department, Hospital | 2 | 2016 | 21 | 0.710 |
Why?
| | Pediatric Emergency Medicine | 1 | 2019 | 17 | 0.690 |
Why?
| | Vertebral Artery | 1 | 2019 | 27 | 0.690 |
Why?
| | Hypovolemia | 1 | 2019 | 14 | 0.690 |
Why?
| | Carotid Artery Injuries | 1 | 2019 | 42 | 0.680 |
Why?
| | Surgeons | 1 | 2022 | 243 | 0.660 |
Why?
| | Doxycycline | 1 | 2018 | 60 | 0.650 |
Why?
| | Liver Neoplasms | 5 | 2015 | 527 | 0.650 |
Why?
| | Medical Errors | 1 | 2019 | 89 | 0.640 |
Why?
| | Craniocerebral Trauma | 1 | 2019 | 146 | 0.610 |
Why?
| | Infant | 18 | 2022 | 8293 | 0.580 |
Why?
| | Hospital Rapid Response Team | 1 | 2016 | 15 | 0.580 |
Why?
| | Sclerosing Solutions | 1 | 2016 | 9 | 0.580 |
Why?
| | Child | 20 | 2023 | 19129 | 0.560 |
Why?
| | Veins | 1 | 2016 | 60 | 0.550 |
Why?
| | Bevacizumab | 1 | 2016 | 124 | 0.550 |
Why?
| | Patient Safety | 1 | 2019 | 281 | 0.550 |
Why?
| | Interferon-alpha | 1 | 2016 | 191 | 0.510 |
Why?
| | Ileal Diseases | 1 | 2014 | 9 | 0.510 |
Why?
| | Child Abuse | 1 | 2019 | 466 | 0.480 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 505 | 0.470 |
Why?
| | Rectum | 2 | 2015 | 157 | 0.470 |
Why?
| | Infant, Newborn | 14 | 2022 | 5255 | 0.460 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2674 | 0.450 |
Why?
| | Receptors, Somatotropin | 1 | 2012 | 9 | 0.440 |
Why?
| | Blood Transfusion | 4 | 2022 | 306 | 0.420 |
Why?
| | Genital Neoplasms, Male | 1 | 2011 | 6 | 0.410 |
Why?
| | Genitalia, Male | 1 | 2011 | 11 | 0.400 |
Why?
| | Patients | 2 | 2023 | 175 | 0.400 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 16 | 0.400 |
Why?
| | Crohn Disease | 1 | 2014 | 197 | 0.400 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 578 | 0.400 |
Why?
| | Disease Management | 1 | 2015 | 571 | 0.400 |
Why?
| | Receptors, Androgen | 1 | 2012 | 134 | 0.390 |
Why?
| | Registries | 3 | 2015 | 1810 | 0.390 |
Why?
| | Child, Preschool | 13 | 2019 | 9491 | 0.380 |
Why?
| | Mesenteric Veins | 1 | 2010 | 10 | 0.380 |
Why?
| | Blood Vessels | 1 | 2012 | 187 | 0.380 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 192 | 0.370 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 325 | 0.370 |
Why?
| | HELLP Syndrome | 1 | 2009 | 6 | 0.370 |
Why?
| | Portal Vein | 1 | 2010 | 90 | 0.350 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 387 | 0.350 |
Why?
| | Neoplasms | 1 | 2023 | 2179 | 0.340 |
Why?
| | Adolescent | 13 | 2023 | 18480 | 0.340 |
Why?
| | Humans | 35 | 2023 | 118972 | 0.330 |
Why?
| | Venous Thrombosis | 1 | 2010 | 147 | 0.330 |
Why?
| | Retrospective Studies | 13 | 2022 | 12978 | 0.300 |
Why?
| | Bone Transplantation | 3 | 2012 | 99 | 0.280 |
Why?
| | Anticoagulants | 1 | 2010 | 559 | 0.270 |
Why?
| | Hemorrhage | 1 | 2009 | 623 | 0.270 |
Why?
| | Recurrence | 2 | 2018 | 975 | 0.250 |
Why?
| | Phlebography | 2 | 2016 | 40 | 0.240 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1510 | 0.230 |
Why?
| | Treatment Outcome | 7 | 2018 | 9342 | 0.230 |
Why?
| | Craniotomy | 3 | 2012 | 69 | 0.220 |
Why?
| | Lymphedema | 2 | 2014 | 21 | 0.220 |
Why?
| | Mosaicism | 1 | 2022 | 62 | 0.220 |
Why?
| | Ascites | 1 | 2022 | 37 | 0.220 |
Why?
| | Noonan Syndrome | 1 | 2022 | 17 | 0.210 |
Why?
| | Radiologists | 1 | 2022 | 38 | 0.210 |
Why?
| | Frontal Bone | 2 | 2012 | 13 | 0.210 |
Why?
| | Parietal Bone | 2 | 2012 | 12 | 0.210 |
Why?
| | Male | 21 | 2018 | 57801 | 0.210 |
Why?
| | Drainage | 1 | 2022 | 157 | 0.210 |
Why?
| | Congenital Abnormalities | 1 | 2022 | 74 | 0.200 |
Why?
| | Incidence | 4 | 2022 | 2424 | 0.200 |
Why?
| | Rabbits | 4 | 2016 | 780 | 0.200 |
Why?
| | Professional Role | 1 | 2022 | 153 | 0.190 |
Why?
| | Surgical Wound Infection | 1 | 2023 | 251 | 0.190 |
Why?
| | Female | 18 | 2018 | 61564 | 0.180 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 287 | 0.170 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.170 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 15 | 0.170 |
Why?
| | Duodenal Obstruction | 1 | 2018 | 5 | 0.170 |
Why?
| | Duodenostomy | 1 | 2018 | 5 | 0.170 |
Why?
| | Skin Neoplasms | 2 | 2016 | 762 | 0.160 |
Why?
| | Duodenum | 1 | 2018 | 67 | 0.160 |
Why?
| | Thoracotomy | 1 | 2018 | 84 | 0.160 |
Why?
| | Risk Factors | 4 | 2023 | 9000 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4596 | 0.150 |
Why?
| | Thoracic Injuries | 1 | 2018 | 63 | 0.150 |
Why?
| | Shock, Hemorrhagic | 1 | 2019 | 206 | 0.150 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 155 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2016 | 13 | 0.150 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 56 | 0.140 |
Why?
| | Risk Assessment | 3 | 2015 | 3057 | 0.130 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 13 | 0.130 |
Why?
| | Pyloric Stenosis, Hypertrophic | 1 | 2015 | 8 | 0.130 |
Why?
| | Shock | 1 | 2016 | 91 | 0.130 |
Why?
| | Drug Carriers | 1 | 2016 | 119 | 0.130 |
Why?
| | Catheters, Indwelling | 1 | 2015 | 81 | 0.130 |
Why?
| | Hypotension | 1 | 2016 | 120 | 0.130 |
Why?
| | Genital Diseases, Male | 1 | 2014 | 15 | 0.120 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 219 | 0.120 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2014 | 27 | 0.120 |
Why?
| | Peritoneal Dialysis | 1 | 2015 | 84 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2022 | 772 | 0.120 |
Why?
| | Penis | 1 | 2014 | 37 | 0.120 |
Why?
| | Scrotum | 1 | 2014 | 25 | 0.120 |
Why?
| | Hirschsprung Disease | 1 | 2015 | 89 | 0.120 |
Why?
| | Laparoscopy | 1 | 2018 | 417 | 0.120 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 91 | 0.120 |
Why?
| | Neonatal Screening | 1 | 2015 | 152 | 0.120 |
Why?
| | Postoperative Care | 1 | 2015 | 237 | 0.120 |
Why?
| | Gastroenterology | 1 | 2015 | 158 | 0.120 |
Why?
| | Global Health | 1 | 2015 | 310 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 178 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1308 | 0.110 |
Why?
| | Arteriovenous Malformations | 1 | 2012 | 24 | 0.110 |
Why?
| | Young Adult | 6 | 2015 | 10793 | 0.110 |
Why?
| | Hamartoma | 1 | 2012 | 20 | 0.110 |
Why?
| | Lipomatosis | 1 | 2011 | 3 | 0.100 |
Why?
| | Prospective Studies | 3 | 2012 | 6471 | 0.100 |
Why?
| | Bone Resorption | 1 | 2012 | 80 | 0.100 |
Why?
| | Cheek | 1 | 2011 | 16 | 0.100 |
Why?
| | Hemangioendothelioma | 1 | 2011 | 13 | 0.100 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 54 | 0.100 |
Why?
| | alpha-Fetoproteins | 1 | 2011 | 33 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1945 | 0.100 |
Why?
| | Biomarkers | 2 | 2012 | 3588 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 1974 | 0.100 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4708 | 0.100 |
Why?
| | Ligation | 1 | 2010 | 82 | 0.090 |
Why?
| | Rare Diseases | 1 | 2011 | 113 | 0.090 |
Why?
| | Length of Stay | 1 | 2015 | 1032 | 0.090 |
Why?
| | Skull | 1 | 2010 | 127 | 0.090 |
Why?
| | Prostheses and Implants | 1 | 2010 | 141 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2016 | 3730 | 0.080 |
Why?
| | Osteogenesis | 1 | 2010 | 213 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1166 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1691 | 0.080 |
Why?
| | Pediatrics | 1 | 2015 | 985 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1864 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3174 | 0.070 |
Why?
| | Colorado | 1 | 2016 | 4196 | 0.070 |
Why?
| | Databases, Factual | 1 | 2011 | 1231 | 0.070 |
Why?
| | Adult | 4 | 2012 | 31512 | 0.070 |
Why?
| | United States | 1 | 2022 | 12555 | 0.070 |
Why?
| | Massachusetts | 2 | 2014 | 141 | 0.060 |
Why?
| | Liver | 1 | 2011 | 1816 | 0.060 |
Why?
| | Prognosis | 1 | 2011 | 3443 | 0.060 |
Why?
| | Splenectomy | 1 | 2022 | 57 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 51 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 116 | 0.050 |
Why?
| | Esophageal Atresia | 1 | 2022 | 27 | 0.050 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 33 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2022 | 86 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 237 | 0.050 |
Why?
| | X-Ray Microtomography | 2 | 2012 | 79 | 0.050 |
Why?
| | Pyridones | 1 | 2022 | 119 | 0.050 |
Why?
| | Survival Rate | 2 | 2015 | 1720 | 0.050 |
Why?
| | Animals | 4 | 2016 | 33381 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 403 | 0.050 |
Why?
| | Spleen | 1 | 2022 | 510 | 0.050 |
Why?
| | Alleles | 1 | 2022 | 832 | 0.050 |
Why?
| | Mutation | 2 | 2022 | 3457 | 0.040 |
Why?
| | Heart Diseases | 1 | 2022 | 341 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 114 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 146 | 0.040 |
Why?
| | Middle Aged | 3 | 2014 | 27617 | 0.040 |
Why?
| | Pregnancy | 1 | 2009 | 5690 | 0.040 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 30 | 0.040 |
Why?
| | Dialysis Solutions | 1 | 2015 | 25 | 0.030 |
Why?
| | Resuscitation | 1 | 2018 | 252 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 79 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 146 | 0.030 |
Why?
| | Constipation | 1 | 2015 | 76 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1795 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 130 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 327 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 185 | 0.030 |
Why?
| | Heart Arrest | 1 | 2018 | 291 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 226 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2016 | 528 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 238 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 2015 | 170 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 296 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 271 | 0.030 |
Why?
| | Gestational Age | 1 | 2015 | 765 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 842 | 0.030 |
Why?
| | Biopsy | 1 | 2015 | 1079 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1474 | 0.030 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2011 | 13 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1223 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 410 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 67 | 0.020 |
Why?
| | Osseointegration | 1 | 2011 | 37 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2011 | 80 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 86 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1527 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 127 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1901 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1868 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 344 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 345 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 982 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 2995 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 246 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 589 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 774 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 709 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 872 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 527 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 5116 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 6412 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2445 | 0.010 |
Why?
| | Aged | 1 | 2014 | 19657 | 0.010 |
Why?
|
|
Kulungowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|